← Leaderboards
Yan Zhang
Virginia Commonwealth University
$14,997,952
Attributed
$16,565,670
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,565,670 · 8
By mechanism
R01$6,247,086 · 2
UG3$4,985,253 · 2
UH3$4,337,165 · 1
R21$849,326 · 2
R03$146,840 · 1
Top collaborators
- Kurt Francis Hauser7 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Shijun Zhang$10,233,701
- Martin K Safo$4,719,250
- Nazira El-Hage$4,324,284
Others in their field
Top investigators on “Affinity”
- Dennis R. Burton · Scripps Research Institute$64,397,776
- James E Crowe · Vanderbilt University Medical Center$53,471,415
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$45,445,140
- Timothy A Springer · Boston Children'S Hospital$41,593,445
- Misty Ward Stevens · Intervexion Therapeutics, Llc$38,187,594
- Rafi Ahmed · Emory University$36,776,987
Research focus
AffinityDesignLigandsBaseOpioidLeadChronicReceptorMolecular ModelingOpioid ReceptorAcutePharmaceutical PreparationsCell LineNaltrexonePharmaceutical ChemistryNeuropharmacologyDockingMultidisciplinaryIn VitroChemical SynthesisMolecularHeroinIn VivoRadioligand
Grant awards (28)
Mu Opioid Receptor Modulator Development to Treat Opioid Use Disorder$1,459,982
UH3 · FY2025 · DA · contact PI
Mu Opioid Receptor Modulator Development to Treat Opioid Use Disorder$1,445,627
UH3 · FY2024 · DA · contact PI
Mu Opioid Receptor Modulator Development to Treat Opioid Use Disorder$1,431,556
UH3 · FY2023 · DA · contact PI
Development of Specific Mu Opioid Receptor Antagonists to Reverse the Acute and Chronic Toxicity of Fentanyls$2,824,374
UG3 · FY2022 · DA · contact PI
Bivalent Ligands as Chemical Probes to Study Opioid Abuse-enhanced HIV Infection$567,877
R01 · FY2021 · DA · contact PI
Mu Opioid Receptor Modulator Development to Treat Opioid Use Disorder$1,039,124
UG3 · FY2020 · DA · contact PI
Bivalent Ligands as Chemical Probes to Study Opioid Abuse-enhanced HIV Infection$567,877
R01 · FY2020 · DA · contact PI
Novel fentanyl derivatives as counteracting agents against fentanyl$125,000
UG3 · FY2020 · DA · contact PI
Mu Opioid Receptor Modulator Development to Treat Opioid Use Disorder$996,755
UG3 · FY2019 · DA · contact PI
Bivalent Ligands as Chemical Probes to Study Opioid Abuse-enhanced HIV Infection$567,877
R01 · FY2019 · DA · contact PI
Non-peptide Mu Opioid Receptor Selective Antagonists$381,250
R01 · FY2019 · DA · contact PI
Bivalent Ligands as Chemical Probes to Study Opioid Abuse-enhanced HIV Infection$507,931
R01 · FY2018 · DA · contact PI
Non-peptide Mu Opioid Receptor Selective Antagonists$381,250
R01 · FY2018 · DA · contact PI
Bivalent Ligands as Chemical Probes to Study Opioid Abuse-enhanced HIV Infection$507,931
R01 · FY2017 · DA · contact PI
Non-peptide Mu Opioid Receptor Selective Antagonists$381,250
R01 · FY2017 · DA · contact PI
Non-peptide Mu Opioid Receptor Selective Antagonists$377,437
R01 · FY2016 · DA · contact PI
Non-peptide Mu Opioid Receptor Selective Antagonists$381,250
R01 · FY2015 · DA · contact PI
Chemical Probes on NeuroAIDS$225,318
R21 · FY2015 · DA · contact PI
Chemical Probes on NeuroAIDS$190,625
R21 · FY2014 · DA · contact PI
Non-peptide Mu Opioid Receptor Selective Antagonists$310,101
R01 · FY2013 · DA · contact PI
Non-peptide Mu Opioid Receptor Selective Antagonists$323,022
R01 · FY2012 · DA · contact PI
Non-peptide Mu Opioid Receptor Selective Antagonists$323,022
R01 · FY2011 · DA · contact PI
Non-peptide Mu Opioid Receptor Selective Antagonists$333,011
R01 · FY2010 · DA · contact PI
Non-peptide Mu Opioid Receptor Selective Antagonists$336,000
R01 · FY2009 · DA · contact PI
Anibamine, a novel CCR5 antagonist as anti-HIV lead compound$230,243
R21 · FY2009 · AI · contact PI
Anibamine, a novel CCR5 antagonist as anti-HIV lead compound$203,140
R21 · FY2008 · AI · contact PI
Chemokine receptor CCR5 antagonists as novel anti-HIV agents$72,340
R03 · FY2007 · AI · contact PI
Chemokine receptor CCR5 antagonists as novel anti-HIV agents$74,500
R03 · FY2006 · AI · contact PI